Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr 22;115(16):3304-13.
doi: 10.1182/blood-2009-07-233304. Epub 2010 Mar 2.

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1

Affiliations

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1

Derek Yecies et al. Blood. .

Abstract

ABT-737 is a small-molecule antagonist of BCL-2 currently under evaluation in clinical trials in the oral form of ABT-263. We anticipate that acquired resistance to this promising drug will inevitably arise. To study potential mechanisms of resistance to ABT-737, we derived resistant lines from initially sensitive OCI-Ly1 and SU-DHL-4 lymphoma cell lines via long-term exposure. Resistance was based in the mitochondria and not due to an inability of the drug to bind BCL-2. Resistant cells had increased levels of BFL-1 and/or MCL-1 proteins, which are not targeted by ABT-737. Proapoptotic BIM was displaced from BCL-2 by ABT-737 in both parental and resistant cells, but in resistant cells, BIM was sequestered by the additional BFL-1 and/or MCL-1. Decreasing MCL-1 levels with flavopiridol, PHA 767491, or shRNA restored sensitivity to ABT-737 resistant cells. MCL-1 was up-regulated not by protein stabilization but rather by increased transcript levels. Surprisingly, in addition to stable increases in MCL-1 transcript and protein in resistant cells, there was a dynamic increase within hours after ABT-737 treatment. BFL-1 protein and transcript levels in resistant cells were similarly dynamically up-regulated. This dynamic increase suggests a novel mechanism whereby modulation of antiapoptotic protein function communicates with nuclear transcriptional machinery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
B-cell lymphoma cells acquire resistance to ABT-737 after long-term exposure. (A) OCI-Ly1 cells were treated with increasing doses of ABT-737 for 48 hours and stained with annexin-V–FITC for flow cytometry analysis. Before treatments, OCI-Ly1 R7 cells were cultured in media containing 320nM ABT-737 and OCI-Ly1 R10 cells in media with 1μM ABT-737. ABT-737 was withdrawn 24 hours before dose response treatment. Viability is shown as a percentage of DMSO-treated control cells. SD is of quadruplicates and is indicated by error bars. (B) OCI-Ly1 R7 and OCI-Ly1 R10 cells were withdrawn (−) from or continued treatment (+) with ABT-737 for 3 weeks. Cells were then washed and treated with increasing doses of ABT-737 for 48 hours, stained with annexin-V–FITC, and assayed by flow cytometry analysis. Viability is shown as a percentage of DMSO-treated control cells. SD is of quadruplicates and is indicated by error bars. (C) SU-DHL-4 and SU-DHL-4 R2 cells were treated with increasing doses of ABT-737 for 12 hours. After treatment, cells were stained with annexin-V–FITC and PI for flow cytometry analysis. Before treatment, SU-DHL-4 R2 cells were cultured in media containing 1μM ABT-737. ABT-737 was withdrawn 3 weeks before dose response treatment. Viability is shown as a percentage of DMSO-treated control cells. SE is of triplicates and is indicated by error bars.
Figure 2
Figure 2
BFL-1 and/or MCL-1 proteins are up-regulated in resistant cell lines and are inducible upon treatment with ABT-737. (A) Immunoblot analysis of OCI-LY1, OCI-LY1 R7, and OCI-LY1 R10 cell line lysates with the indicated antibodies. − indicates that ABT-737 was withdrawn for 3 weeks; +, continuous culture with ABT-737. Unpictured antibody controls confirmed the efficacy of the BCL-XL and BFL-1 antibodies used in this assay. These results are representative of 3 independent experiments. (B) OCI-Ly1 R7 cells were removed from ABT-737–containing media for 3 weeks. ABT-737 was added back to culture for the indicated time frame at 320nM. Whole-cell lysates were made after treatment and analyzed by immunoblot. DMSO was used as a solvent-only negative control. These results are representative of 3 independent experiments. (C) SU-DHL-4 R2 cells were removed from ABT-737–containing media for 3 weeks. SU-DHL-4 and SU-DHL-4 R2 cells were treated with 1μM ABT-737 or DMSO for 12 hours after pretreatment with 10μM ZVAD.fmk or DMSO for 1 hour as indicated. Whole-cell lysates were made after treatment and analyzed by immunoblot. These results are representative of 3 independent experiments. ND indicates that these samples were not analyzed.
Figure 3
Figure 3
BH3 profiling reveals a mitochondrial basis for acquired resistance to ABT-737. (A) Mitochondria were isolated from OCI-Ly1 and OCI-Ly1 R10 cells and treated with different concentrations of peptides. Cytochrome c release was measured by ELISA. Shown is the average and SE of 3 independent experiments. (B) Mitochondria were isolated from SU-DHL-4 and SU-DHL-4 R2 cells and treated with different peptides. Cytochrome c release was measured by ELISA. Shown is the average and SE of 3 independent experiments. In both cases, ABT-737 was removed from culture medium for at least 1 week.
Figure 4
Figure 4
ABT-737 reaches its target, BCL-2, in sensitive and resistant cells, and increased MCL-1 and BFL-1 sequester BIM displaced from BCL-2 by ABT-737. (A) OCI-LY1 cells were treated with 1μM ABT-737 for 4 hours after pretreatment with 10μM ZVAD.fmk for 30 minutes as indicated. Cells were lysed with 1% CHAPS lysis buffer. Lysates were immunoprecipitated using BCL-2– and MCL-1–specific antibodies. The resulting immunoprecipitated and coimmunoprecipitated proteins were analyzed by immunoblot alongside whole-cell lysates. *IgG heavy chain. (B) OCI-Ly1 R10 cells were treated with DMSO or 1μM ABT-737 (+) for 4 hours. Cells were lysed with 1% CHAPS lysis buffer. A total of 100 μg of lysate were immunoprecipitated with the BCL-2 (6C8) antibody. The resulting immunoprecipitated and coimmunoprecipitated proteins were analyzed by immunoblot alongside whole-cell lysates. These results are representative of 3 independent experiments. (C) OCI-Ly1 R10 cells were treated and lysed as in panel B. A total of 100 μg of lysate were immunoprecipitated with an MCL-1–specific antibody. The resulting immunoprecipitated and coimmunoprecipitated proteins were analyzed by immunoblot alongside whole-cell lysates. These results are representative of 3 independent experiments. (D) SU-DHL-4 cells were treated with DMSO or 1μM ABT-737 (+) for 12 hours after pretreatment with 10μM ZVAD.fmk for 1 hour. SU-DHL-4 R2 cells were treated with DMSO or 1μM ABT-737 (+) for 12 hours. Cells were lysed with 1% CHAPS lysis buffer. Lysates were immunoprecipitated using a BCL-2–specific antibody (6C8). The resulting immunoprecipitated and coimmunoprecipitated proteins were analyzed by immunoblot. (E) SU-DHL-4 and SU-DHL-4 R2 cells were treated and lysed as in panel D. Lysates were immunoprecipitated using a BIM-specific antibody. The resulting immunoprecipitated and coimmunoprecipitated proteins were analyzed by immunoblot. (F) Immunoblot analysis of the whole-cell lysates used for immunoprecipitation in panels D and E.
Figure 5
Figure 5
MCL-1 and BFL-1 are transcriptionally up-regulated in resistant cells. (A) OCI-Ly1, OCI-Ly1 R7, and OCI-LY1 R10 cells were treated with 20 μg/mL CHX for the time indicated. Cells were lysed immediately after treatment and subject to immunoblot analysis. These results are representative of 3 independent experiments. (B) Cells were cultured in the absence of ABT-737 for 2 weeks. RNA was isolated and MCL-1 fold change was analyzed by quantitative PCR. (C) Cells were cultured in the absence of ABT-737 for 2 weeks and then treated with DMSO or 250nM ABT-737 for 16 hours. RNA was isolated and MCL-1 fold change was analyzed by quantitative PCR. (D) OCI-Ly1 and OCI-Ly1 R10 cells were cultured in the absence of ABT-737 for 3 weeks. Cells were then treated with 20μM ZVAD.fmk for 45 minutes before treatment with 1μM ABT-737 for the time indicated. RNA was isolated and MCL-1 fold change was analyzed by quantitative PCR. (E) SU-DHL-4 and SU-DHL-4 R2 cells were cultured in the absence of ABT-737 for 3 weeks and treated and analyzed as in panel D. (F) RNA from panel E was used to assay BFL-1 fold change by quantitative PCR. Error bars in panels B through F indicate the SEM. RNA levels from the untreated parental cell lines were set to 1.
Figure 6
Figure 6
CDK9 inhibition or shRNA decrease MCL-1 levels and restore sensitivity to ABT-737. (A) Immunoblot analysis of OCI-LY1 R10 whole-cell lysates after 4 hours of flavopiridol treatment with different doses. Viability was assayed by annexin-V–FITC staining and flow cytometry. (B) OCI-LY1 and OCI-LY1 R10 cells were treated for 4 hours with DMSO or 300nM flavopiridol in combination with 0 or 250nM ABT-737, stained with annexin-V–FITC, and analyzed by flow cytometry. This experiment was performed in quadruplicate. (C) Immunoblot analysis of SU-DHL-4 R2 whole-cell lysates after 4 hours of flavopiridol treatment with different doses. (D) SU-DHL-4 and SU-DHL-4 R2 cells were treated for 12 hours with DMSO or 500nM ABT-737. During the last 4 hours of ABT-737 treatment, cells were treated with DMSO or 300nM flavopiridol. Cells were then stained with annexin-V–FITC and PI and analyzed by flow cytometry. The experiment was performed in triplicate. (E) Immunoblot analysis of MCL-1 knockdown by shRNA in single-cell clones. (F) Clones were chosen based on knockdown in panel E and tested for sensitivity by treatment with 500nM ABT-737 or DMSO. This experiment was performed in quadruplicate. All P values were determined by 2-tailed t tests. (G) Immunoblot analysis of OCI-LY1 R10 whole-cell lysates after 4 hours of PHA 767491 treatment with different doses. (H) OCI-LY1 and OCI-LY1 R10 cells were treated for 4 hours with DMSO or 3000nM PHA 767491 in combination with 0 or 1μM ABT-737, stained with annexin-V–FITC, and analyzed by flow cytometry. (I) Immunoblot analysis of SU-DHL-4 R2 whole-cell lysates after 4 hours of PHA 767491 treatment with different doses. (J) SU-DHL-4 and SU-DHL-4 R2 cells were treated for 12 hours with DMSO or 1μM ABT-737. During the last 4 hours of ABT-737 treatment, cells were treated with DMSO or 3000nM PHA 76741. Cells were then stained with annexin-V–FITC and PI and analyzed by flow cytometry. Error bars for panels B, D, and F represent SEM of independent quadruplicate, triplicate, and quadruplicate experiments, respectively. Error bars in panels H and J are representative of technical replicates, and the graphs presented are representative of 2 independent experiments.
Figure 7
Figure 7
Proposed mechanism of acquired resistance. In sensitive cells, BIM is displaced from BCL-2, inducing BAX activation and apoptosis. In resistant cells, BIM is still displaced, but is captured by BFL-1 and/or MCL-1, preventing BAX activation and maintaining survival.

References

    1. Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell. 1985;41(3):899–906. - PubMed
    1. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A. 1985;82(21):7439–7443. - PMC - PubMed
    1. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228(4706):1440–1443. - PubMed
    1. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature. 1990;348(6299):331–333. - PubMed
    1. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature. 1991;349(6306):254–256. - PubMed

Publication types

MeSH terms